Changes in microRNA (miRNA) expression have been shown to be associated with a variety of normal physiological processes as well as diseases including cancer. This funding will allow Bioo Scientific to develop a rapid, quantitative technology to measure miRNA expression in living cells or tumor tissue.
According to Dr. Masoud Toloue, Senior Scientist at Bioo Scientific, “Most cancer diagnostic tests tend to focus on proteins expressed from oncogenes which do not lend well to early detection. With the recent classification of certain microRNAs as anti-tumorigenic or oncogenic, our work will be centered on developing diagnostic markers from these non-coding genes. Our ultimate goal will be to quickly assess microRNA profiles from a patient’s tissue.”